New drug cocktail aims to extend life in aggressive brain cancer
NCT ID NCT03213002
First seen Jun 03, 2026 · Last updated Jun 17, 2026 · Updated 2 times
Summary
This study tests whether adding the chemotherapy drug capecitabine to the standard treatment temozolomide can help people with newly diagnosed glioblastoma (a fast-growing brain cancer) live longer without their cancer getting worse. About 67 adults who have completed initial radiation and chemo will take both drugs by mouth. The goal is to see if the combination is safe and more effective than standard care alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lenox Hill Brain Tumor Center
RECRUITINGNew York, New York, 10075, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.